Case Report
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2014; 20(42): 15920-15924
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15920
Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors
Yoshiaki Kawaguchi, Atsuko Maruno, Yohei Kawashima, Hiroyuki Ito, Masami Ogawa, Tetsuya Mine
Yoshiaki Kawaguchi, Atsuko Maruno, Yohei Kawashima, Hiroyuki Ito, Masami Ogawa, Tetsuya Mine, Department of Gastroenterology, Tokai University School of Medicine, Isehara 259-1193, Japan
Author contributions: Kawaguchi Y contributed mainly to this work; Kawaguchi Y wrote the paper; Maruno A, Kawashima Y, Ito H, Ogawa M and Mine T supported and checked the paper.
Correspondence to: Yoshiaki Kawaguchi, MD, PhD, Department of Gastroenterology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan. y711kawa@is.icc.u-tokai.ac.jp
Telephone: +81-463-931121 Fax: +81-463-937134
Received: February 27, 2014
Revised: May 21, 2014
Accepted: June 14, 2014
Published online: November 14, 2014
Core Tip

Core tip: This is the first case report of amenorrhea as a rare adverse event associated with everolimus treatment for pancreatic neuroendocrine tumor. As the younger women might be included in pancreatic neuroendocrine tumors patients, we should put this adverse event into consideration.